(0.07%) 5 473.13 points
(0.12%) 39 160 points
(0.38%) 17 786 points
(0.07%) $80.89
(-3.66%) $2.66
(-0.79%) $2 312.40
(0.18%) $28.92
(3.67%) $1 022.60
(0.28%) $0.936
(0.68%) $10.68
(0.43%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye...
Stats | |
---|---|
今日成交量 | 862 |
平均成交量 | 38 046 |
市值 | 487.97M |
EPS | $-0.440 ( Q1 | 2024-05-08 ) |
下一个收益日期 | ( $-0.410 ) 2024-09-03 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
65.01 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.103 (0.88%) |
Oculis Holding AG 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Oculis Holding AG 财务报表
Annual | 2023 |
营收: | $883 000 |
毛利润: | $-28.36M (-3 212.23 %) |
EPS: | $-2.97 |
FY | 2023 |
营收: | $883 000 |
毛利润: | $-28.36M (-3 212.23 %) |
EPS: | $-2.97 |
FY | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-1.180 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Oculis Holding AG
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company\'s lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。